{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:56:30Z","timestamp":1777784190259,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Artif Organs"],"published-print":{"date-parts":[[2003,6]]},"abstract":"\n Purpose<\/jats:title>\n The efficacy of the vitamin D analog paricalcitol has mainly been shown in short-term studies. There are limited data regarding long-term treatment with this agent. This purpose of this study was to determine long-term effects of paricalcitol therapy on parathyroid hormone (PTH) suppression and serum levels of calcium, phosphorus and calcium-phosphorus product (Ca \u00d7 P).<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n Patients who received paricalcitol for \u2265 3 months had the following data collected: demographics, drug dosage, serum PTH, corrected serum calcium concentration, serum phosphorus concentrations and serum Ca \u00d7 P values.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Sixteen patients received paricalcitol for a mean of 18 months. The mean \u00b1 SD dose of paricalcitol was 0.13 \u00b1 0.12 mcg\/kg. The mean \u00b1 SD pre-paricalcitol serum PTH concentration was 705 \u00b1 423 pg\/mL. PTH concentration did not change significantly over the duration of treatment (mean \u00b1 SD: 821 \u00b1 480 pg\/mL). The number of patients who had at least one corrected serum calcium concentration \u2265 11.5 mg\/dL, one serum phosphorus concentration \u2265 6.5 mg\/dL, or one Ca \u00d7 P level \u2265 70 were 75%, 94% and 82%, respectively. Hypercalcemia and elevated Ca \u00d7 P value resulted in a mean of 17% of doses being withheld during therapy.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n During the study, PTH was not adequately suppressed by paricalcitol. This was primarily attributed to withholding paricalcitol doses due to elevated serum calcium and Ca \u00d7 P levels.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/039139880302600606","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T01:23:07Z","timestamp":1516324987000},"page":"484-490","source":"Crossref","is-referenced-by-count":4,"title":["Long-Term Therapy with Paricalcitol for Secondary Hyperparathyroidism in Hemodialysis Patients"],"prefix":"10.1177","volume":"26","author":[{"given":"A. Barton","family":"Pai","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago - Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lin","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago - Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.L.","family":"Arruda","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Illinois at Chicago, Chicago - Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H.","family":"Lau","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Chicago - Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,6,1]]},"reference":[{"key":"bibr1-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118701"},{"key":"bibr2-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118224"},{"key":"bibr3-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110714"},{"key":"bibr4-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330307"},{"key":"bibr5-039139880302600606","first-page":"S114","volume":"18","author":"Fournier A.","year":"1986","journal-title":"Kidney Int"},{"key":"bibr6-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9808142"},{"key":"bibr7-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90571-0"},{"key":"bibr8-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9808143"},{"key":"bibr9-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9808145"},{"key":"bibr10-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.32.1.56"},{"key":"bibr11-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28114"},{"key":"bibr12-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9629(15)40549-X"},{"key":"bibr13-039139880302600606","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.suppl_3.57"}],"container-title":["The International Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/039139880302600606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/039139880302600606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:39:53Z","timestamp":1777491593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/039139880302600606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["10.1177\/039139880302600606"],"URL":"https:\/\/doi.org\/10.1177\/039139880302600606","relation":{},"ISSN":["0391-3988","1724-6040"],"issn-type":[{"value":"0391-3988","type":"print"},{"value":"1724-6040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}